DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Abstract Background Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combination with rituximab yielded high objective respons...

Full description

Bibliographic Details
Main Authors: Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Alexandra Aronin, Shira Amsili, Elina Zorde-Khvalevsky, Yosi Gozlan, Martijn Vlaming, Gerwin Huls, Tom van Meerten, Michal Elhalel Dranitzki, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Ayelet Chajut, Edwin Bremer
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
B cell lymphoma
CD47-SIRPα ‘don’t eat me’ signaling
Phagocytosis
T cell co-stimulation
4-1BB
Online Access:https://doi.org/10.1186/s13046-022-02256-x

Internet

https://doi.org/10.1186/s13046-022-02256-x

Similar Items